The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator
Ninos Ayez, Cornelis Verhoef(Erasmus MC Cancer Institute), Joost Rothbarth(Erasmus MC Cancer Institute), Dirk J. Grünhagen(Erasmus MC), E. van Meerten(Erasmus MC Cancer Institute), Alexander M.M. Eggermont(University Medical Center Utrecht), Eric P. van der Stok(Erasmus MC Cancer Institute)
Cited by 81
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k